Search PubMed⌕ Search

Biomedical subjects

C Rozman

Publications and source records attributed to C Rozman.

At least 289 records · Page 16Linked to original sources
PubMed1988

Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages.

Ten previously untreated patients with early B cell chronic lymphocytic leukemia (B-CLL) (seven in Rai's stage 0, three in stage I) were given recombinant alpha 2-interferon (alpha 2IF) (2 X 10(6) U/m2 intramuscularly three times a week for a minimum of 14 weeks) to assess its effectiveness. All patients were evaluable for response to therapy and toxicity. No complete response was achieved. In all cases a definite, although transient reduction in the absolute number of peripheral blood lymphocytes was observed. In eight patients an increase in the absolute number of granulocytes was detected. None of the patients experienced severe hematologic toxicity. Fatigue, malaise, and fever were the more common side effects, but all patients were able to finish their treatment as planned. The results of this pilot study suggest that low doses of recombinant alpha 2-IF have some activity in early and previously untreated B-CLL and that further studies of IF effectiveness in B-CLL seem warranted.

Adult↗
PubMed1988

Immunohistochemical study of bone marrow sections in CLL.

T lymphocytes and dendritic reticulum cells (DRC) were studied in frozen-cut bone marrow sections of 35 patients with chronic lymphocytic leukemia (CLL) (infiltration patterns: interstitial 8, nodular 6, mixed 9, diffuse 12) and 13 cases of low grade non Hodgkin's lymphoma (NHL) (centroblastic/centrocytic 7, centrocytic 3, lymphoplasmacytoid 3) with bone marrow involvement. In contrast to the usual findings in normal bone marrow, in CLL and low grade NHL CD4 positive cells were more numerous than CD8 positive cells. Whereas in NHL CDR were large and occupied all the nodule, in CLL were small and located in the center of the nodule. These findings can be of interest in the study and differential diagnosis of lymphoproliferative disorders.

Antigens, Differentiation, T-Lymphocyte↗
PubMed1988

Advances in therapy of chronic lymphocytic leukaemia.

Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disorder characterized by the progressive accumulation of clonal small mature-looking lymphocytes, usually of B cell origin. In addition to a better understanding of many biological features, during the last 10-15 years a great progress has been made in the prognostic characterization of the disease. The therapeutic achievements, however, have been less impressive. The possibility to identify patients with different prognosis has renewed interest in the treatment of this disorder. A considerable number of controlled trials have been performed or are in course, and new perspectives for CLL treatment are emerging. Basically four different kinds of measures are used: 1) chemotherapy, 2) radiotherapy, 3) adjuvant measures and 4) new modalities.

Combined Modality Therapy↗
PubMed1987

Criteria for severe aplastic anaemia.

To study the validity of currently accepted international criteria for severe aplastic anaemia, 213 consecutive cases of bone marrow aplasia from a single institution were analysed. The distribution percentiles of peripheral blood values and multivariate analysis showed that the current reticulocyte count limit of 1% (corrected for haematocrit) is inadequate an an indicator of severe disease and should be substantially lowered. Since the choice of treatment in aplastic anaemia may depend on the prognosis current criteria for severe aplastic anaemia should be modified.

Adult↗